Veracyte (VCYT) Total Non-Current Liabilities (2012 - 2026)
Veracyte's (VCYT) quarterly Total Non-Current Liabilities came in at $91.7 million in Q1 2026, down 23.49% year-on-year from $119.9 million in Q1 2025, and down 3.29% quarter-over-quarter from $94.9 million in Q4 2025.
Veracyte (VCYT) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Veracyte has disclosed Total Non-Current Liabilities across 11 years of filings, most recently posting $91.7 million for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $91.7 million, down 23.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $91.7 million (down 23.49% YoY), and the FY2025 annual result was $94.9 million, down 23.29% from the prior year.
- Total Non-Current Liabilities came in at $91.7 million for Q1 2026 at Veracyte, down from $94.9 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $123.7 million in Q4 2024 to a low of $70.0 million in Q4 2023.
- The 5-year median for Total Non-Current Liabilities is $84.8 million (2024), against an average of $90.5 million.
- Across the five-year window, Total Non-Current Liabilities soared 77.21% in 2022 and decreased 23.49% in 2026, its largest moves.
- Veracyte's Total Non-Current Liabilities stood at $80.3 million in 2022, then retreated by 12.79% to $70.0 million in 2023, then soared by 76.61% to $123.7 million in 2024, then fell by 23.29% to $94.9 million in 2025, then dropped by 3.29% to $91.7 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $91.7 million (Q1 2026), $94.9 million (Q4 2025), and $109.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Waters | 30,529.42 Bn | 30,528.96 Bn | 1.11 Bn | 6.97 Bn |
| 2 | Thermo Fisher Scientific | 183.75 Bn | 180.50 Bn | 7.74 Bn | 56.93 Bn |
| 3 | Danaher | 133.13 Bn | 127.43 Bn | 3.59 Bn | 25.03 Bn |
| 4 | Idexx Laboratories | 46.14 Bn | 45.94 Bn | 722.74 Mn | 529.54 Mn |
| 5 | Agilent Technologies | 38.20 Bn | 36.39 Bn | 990.00 Mn | 5.45 Bn |
| 6 | Natera | 31.50 Bn | 30.40 Bn | 696.04 Mn | 737.18 Mn |
| 7 | Iqvia Holdings | 31.34 Bn | 29.36 Bn | 1.36 Bn | 22.71 Bn |
| 8 | Illumina | 24.51 Bn | 23.36 Bn | 721.00 Mn | 3.53 Bn |
| 9 | Mettler Toledo International | 23.53 Bn | 23.47 Bn | 555.82 Mn | 3.42 Bn |
| 10 | Veracyte | 3.91 Bn | 3.65 Bn | 101.16 Mn | 91.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91.74 Mn |
| Dec 31, 2025 | 94.85 Mn |
| Sep 30, 2025 | 109.54 Mn |
| Jun 30, 2025 | 122.47 Mn |
| Mar 31, 2025 | 119.91 Mn |
| Dec 31, 2024 | 123.66 Mn |
| Sep 30, 2024 | 84.75 Mn |
| Jun 30, 2024 | 99.60 Mn |
| Mar 31, 2024 | 80.90 Mn |
| Dec 31, 2023 | 70.02 Mn |
| Sep 30, 2023 | 70.11 Mn |
| Jun 30, 2023 | 73.54 Mn |
| Mar 31, 2023 | 75.07 Mn |
| Dec 31, 2022 | 80.29 Mn |
| Sep 30, 2022 | 76.63 Mn |
| Jun 30, 2022 | 77.69 Mn |
| Mar 31, 2022 | 87.02 Mn |
| Dec 31, 2021 | 85.59 Mn |
| Sep 30, 2021 | 77.39 Mn |
| Jun 30, 2021 | 51.79 Mn |